Entero Therapeutics, Inc. Common Stock (ENTO) Income Statement (2024 - 2025)
Income Statement report data from Jun 30, 2024 to Sep 30, 2025 for Entero Therapeutics, Inc. Common Stock (ENTO).
Reported currency: USD
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | |
|---|---|---|---|---|---|---|
Operating Expenses | ||||||
Research And Development | 10K (0.00%) | 10K (-50.00%) | 20K (0.00%) | 20K (-90.48%) | 210K (-4.55%) | 220K |
Selling General And Administrative | 930K (+47.62%) | 630K (-22.22%) | 810K (-31.36%) | 1.18M (-30.18%) | 1.69M (-47.35%) | 3.21M |
Operating Expenses | 930K (+45.31%) | 640K (-21.95%) | 820K (-31.67%) | 1.20M (-36.51%) | 1.89M (-44.90%) | 3.43M |
Operating Income | ||||||
Operating Income | -930.00K (+45.31%) | -640.00K (-21.95%) | -820.00K (-31.67%) | -1.20M (-36.51%) | -1.89M (-44.90%) | -3.43M |
EBITDA | -930.00K (+45.31%) | -640.00K (-21.95%) | -820.00K (-31.67%) | -1.20M (-36.51%) | -1.89M (-44.25%) | -3.39M |
Other Income / Expenses | ||||||
Interest Income | -40.00K (0.00%) | -40.00K | - | - | - | - |
Interest Expense | - | - | -20.00K | - | - | - |
Net Interest Income | -40.00K (0.00%) | -40.00K | 20K | - | - | - |
Other Non Operating Income | - | - | -110.00K | 10K | - | - |
Net Income | ||||||
Income Before Tax | -970.00K (+44.78%) | -670.00K (-29.47%) | -950.00K (-20.17%) | -1.19M (-37.37%) | -1.90M (-44.61%) | -3.43M |
Income Tax Expense | - | - | - | - | - | 4.26M |
Net Income From Continuing Operations | -1.15M (+15.00%) | -1.00M (+5.26%) | -950.00K (-92.24%) | -12.24M (+374.42%) | -2.58M (-70.72%) | -8.81M |
Net Income | -1.15M (+15.00%) | -1.00M (+5.26%) | -950.00K (-92.24%) | -12.24M (+374.42%) | -2.58M (-70.72%) | -8.81M |